NO972176L - Konjugater av BDNF og NT-3 med en vannopplöselig polymer - Google Patents
Konjugater av BDNF og NT-3 med en vannopplöselig polymerInfo
- Publication number
- NO972176L NO972176L NO972176A NO972176A NO972176L NO 972176 L NO972176 L NO 972176L NO 972176 A NO972176 A NO 972176A NO 972176 A NO972176 A NO 972176A NO 972176 L NO972176 L NO 972176L
- Authority
- NO
- Norway
- Prior art keywords
- bdnf
- polypeptide
- polyethylene glycol
- water
- soluble polymer
- Prior art date
Links
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title claims description 124
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title claims description 124
- 229920003169 water-soluble polymer Polymers 0.000 title claims description 33
- 239000002202 Polyethylene glycol Substances 0.000 claims description 66
- 229920001223 polyethylene glycol Polymers 0.000 claims description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 229920001184 polypeptide Polymers 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 43
- 229920000642 polymer Polymers 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000005932 reductive alkylation reaction Methods 0.000 claims description 18
- 210000002161 motor neuron Anatomy 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 12
- -1 poly(N-vinylpyrrolidone) Polymers 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 210000005013 brain tissue Anatomy 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 3
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 59
- 108090000742 Neurotrophin 3 Proteins 0.000 description 59
- 229940032018 neurotrophin 3 Drugs 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 18
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 18
- 238000005917 acylation reaction Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000010933 acylation Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000001815 facial effect Effects 0.000 description 14
- 230000006320 pegylation Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000001488 sodium phosphate Substances 0.000 description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
- 238000005804 alkylation reaction Methods 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 230000029936 alkylation Effects 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 238000001212 derivatisation Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000012064 sodium phosphate buffer Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000009145 protein modification Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000003523 substantia nigra Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000000256 facial nerve Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000003827 glycol group Chemical group 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 210000003594 spinal ganglia Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241001573498 Compacta Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- 108091006006 PEGylated Proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229940124606 potential therapeutic agent Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007441 retrograde transport Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 210000004515 ventral tegmental area Anatomy 0.000 description 2
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 102000051542 human BDNF Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Sludge (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Treatment Of Water By Ion Exchange (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/340,131 US5770577A (en) | 1994-11-14 | 1994-11-14 | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| PCT/US1995/014658 WO1996015146A1 (en) | 1994-11-14 | 1995-11-13 | Conjugates of bdnf and nt-3 with a water-soluble polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972176D0 NO972176D0 (no) | 1997-05-12 |
| NO972176L true NO972176L (no) | 1997-07-14 |
Family
ID=23332020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972176A NO972176L (no) | 1994-11-14 | 1997-05-12 | Konjugater av BDNF og NT-3 med en vannopplöselig polymer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5770577A (ko) |
| EP (1) | EP0792288B1 (ko) |
| JP (1) | JPH10508853A (ko) |
| KR (1) | KR100253762B1 (ko) |
| CN (1) | CN1173183A (ko) |
| AT (1) | ATE175973T1 (ko) |
| AU (1) | AU694589B2 (ko) |
| CA (1) | CA2204640C (ko) |
| CZ (1) | CZ137597A3 (ko) |
| DE (1) | DE69507507T2 (ko) |
| DK (1) | DK0792288T3 (ko) |
| ES (1) | ES2126331T3 (ko) |
| GR (1) | GR3029790T3 (ko) |
| HU (1) | HUT77747A (ko) |
| IL (1) | IL115965A (ko) |
| MX (1) | MX9703362A (ko) |
| NO (1) | NO972176L (ko) |
| NZ (1) | NZ296452A (ko) |
| RU (1) | RU2136694C1 (ko) |
| SK (1) | SK283083B6 (ko) |
| WO (1) | WO1996015146A1 (ko) |
| ZA (1) | ZA959653B (ko) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JPH10212241A (ja) * | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Ｂｄｎｆを安定に含有する製剤 |
| EP0938499A1 (en) | 1996-07-19 | 1999-09-01 | Amgen Inc. | Analogs of cationic proteins |
| ATE406907T1 (de) * | 1998-10-28 | 2008-09-15 | Cornell Res Foundation Inc | Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4 |
| US6656474B1 (en) * | 1999-01-15 | 2003-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| EP1264844A4 (en) * | 2000-02-29 | 2004-08-18 | Ltt Bio Pharma Co Ltd | BDNF MODIFIED |
| US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| JP4259868B2 (ja) * | 2001-02-01 | 2009-04-30 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ニューブラスチンのポリマー結合体および同様の使用方法。 |
| US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| JP2006519170A (ja) * | 2002-12-26 | 2006-08-24 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体 |
| SI2246362T1 (sl) * | 2003-01-31 | 2014-04-30 | Biogen Idec Ma Inc. | Polimerni konjugati mutiranega neoblastina |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| NZ543365A (en) | 2003-04-18 | 2009-02-28 | Biogen Idec Inc | Polymer-conjugated glycosylated neublastin |
| BRPI0506793A (pt) * | 2004-02-20 | 2007-05-22 | Rinat Neuroscience Corp | métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 |
| JP4960865B2 (ja) | 2004-06-24 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄に関連する状態の処置 |
| US8722862B2 (en) * | 2004-08-19 | 2014-05-13 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
| EA013565B1 (ru) * | 2004-08-19 | 2010-06-30 | Байоджен Айдек Ма Инк. | Варианты полипептидов нейбластина, способы их получения и их применение |
| CA2610771A1 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| EP1988920A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| CN101400367A (zh) * | 2006-02-02 | 2009-04-01 | 瑞纳神经科学公司 | 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法 |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| EP1993590B1 (en) * | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| US20080131431A1 (en) * | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| JP2010513461A (ja) * | 2006-12-20 | 2010-04-30 | ライナット ニューロサイエンス コーポレイション | 自己免疫障害を治療するためのＴｒｋＢアゴニスト |
| TWI445544B (zh) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
| US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| EP2205071B1 (en) * | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
| CN101918540B (zh) * | 2007-11-08 | 2016-05-11 | 比奥根Ma公司 | Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用 |
| CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
| CA2803646A1 (en) | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| MX2014013950A (es) | 2012-05-14 | 2015-02-17 | Biogen Idec Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
| CN102964442B (zh) * | 2012-11-19 | 2015-04-29 | 未名生物医药有限公司 | 一种聚乙二醇同神经生长因子结合物的制备方法 |
| CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| CN111514279B (zh) * | 2020-06-16 | 2023-07-18 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用 |
| CN115025723A (zh) * | 2022-05-10 | 2022-09-09 | 吉林大学 | 经神经生长因子及多巴胺改良的peg-plga微球 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US5169762A (en) * | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
| DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| CA1340810C (en) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| ATE135370T1 (de) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| GR1000980B (el) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο. |
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| AU654302B2 (en) * | 1990-09-25 | 1994-11-03 | Genentech Inc. | Novel neurothrophic factor |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5389529A (en) * | 1991-06-12 | 1995-02-14 | Regeneron Pharmaceuticals, Inc. | Modified lamβ signal sequence and processes for producing recombinant neurotrophins |
| NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5260308A (en) * | 1991-11-06 | 1993-11-09 | Mayo Foundation For Medical Education And Research | Method to increase permeability of the blood-nerve/brain barriers to proteins |
| US5468872A (en) * | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
-
1994
- 1994-11-14 US US08/340,131 patent/US5770577A/en not_active Expired - Lifetime
-
1995
- 1995-11-12 IL IL11596595A patent/IL115965A/en active IP Right Grant
- 1995-11-13 JP JP8516219A patent/JPH10508853A/ja not_active Ceased
- 1995-11-13 DE DE69507507T patent/DE69507507T2/de not_active Expired - Lifetime
- 1995-11-13 NZ NZ296452A patent/NZ296452A/xx unknown
- 1995-11-13 CN CN95197321A patent/CN1173183A/zh active Pending
- 1995-11-13 HU HU9800671A patent/HUT77747A/hu unknown
- 1995-11-13 SK SK571-97A patent/SK283083B6/sk unknown
- 1995-11-13 CA CA002204640A patent/CA2204640C/en not_active Expired - Fee Related
- 1995-11-13 KR KR1019970703211A patent/KR100253762B1/ko not_active IP Right Cessation
- 1995-11-13 RU RU97107892/04A patent/RU2136694C1/ru not_active IP Right Cessation
- 1995-11-13 MX MX9703362A patent/MX9703362A/es not_active IP Right Cessation
- 1995-11-13 CZ CZ971375A patent/CZ137597A3/cs unknown
- 1995-11-13 AU AU41071/96A patent/AU694589B2/en not_active Ceased
- 1995-11-13 EP EP95939123A patent/EP0792288B1/en not_active Expired - Lifetime
- 1995-11-13 AT AT95939123T patent/ATE175973T1/de not_active IP Right Cessation
- 1995-11-13 WO PCT/US1995/014658 patent/WO1996015146A1/en not_active Application Discontinuation
- 1995-11-13 ES ES95939123T patent/ES2126331T3/es not_active Expired - Lifetime
- 1995-11-13 DK DK95939123T patent/DK0792288T3/da active
- 1995-11-14 ZA ZA9509653A patent/ZA959653B/xx unknown
-
1997
- 1997-05-12 NO NO972176A patent/NO972176L/no not_active Application Discontinuation
-
1999
- 1999-03-23 GR GR990400878T patent/GR3029790T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2204640C (en) | 2001-01-09 |
| WO1996015146A1 (en) | 1996-05-23 |
| NZ296452A (en) | 1999-01-28 |
| SK283083B6 (sk) | 2003-02-04 |
| ES2126331T3 (es) | 1999-03-16 |
| GR3029790T3 (en) | 1999-06-30 |
| DK0792288T3 (da) | 1999-09-13 |
| IL115965A0 (en) | 1996-01-31 |
| ATE175973T1 (de) | 1999-02-15 |
| AU694589B2 (en) | 1998-07-23 |
| JPH10508853A (ja) | 1998-09-02 |
| EP0792288A1 (en) | 1997-09-03 |
| AU4107196A (en) | 1996-06-06 |
| NO972176D0 (no) | 1997-05-12 |
| ZA959653B (en) | 1997-08-26 |
| EP0792288B1 (en) | 1999-01-20 |
| CZ137597A3 (cs) | 1998-10-14 |
| IL115965A (en) | 2001-01-28 |
| RU2136694C1 (ru) | 1999-09-10 |
| US5770577A (en) | 1998-06-23 |
| DE69507507D1 (de) | 1999-03-04 |
| CN1173183A (zh) | 1998-02-11 |
| HUT77747A (hu) | 1998-07-28 |
| MX9703362A (es) | 1997-08-30 |
| SK57197A3 (en) | 1999-02-11 |
| DE69507507T2 (de) | 1999-05-27 |
| KR100253762B1 (ko) | 2000-05-01 |
| CA2204640A1 (en) | 1996-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO972176L (no) | Konjugater av BDNF og NT-3 med en vannopplöselig polymer | |
| MXPA97003362A (en) | Conjugates of bdnf and nt-3 with a polymer solubleen a | |
| JP5241037B2 (ja) | 截形グリア細胞系由来神経栄養因子 | |
| AU615810B2 (en) | Osteogenic factors | |
| SK1499A3 (en) | Analogs of cationic proteins | |
| BG62975B1 (bg) | Рекомбинантни протеини на затлъстяването | |
| US20160060317A1 (en) | Novel neurturin conjugates for pharmaceutical use | |
| EP0409727A2 (en) | Purification of nerve growth factor (beta subunit) by subunit exchange chromatography | |
| JPH05238941A (ja) | 薬剤組成物 | |
| CA2079291A1 (en) | Activities of heparin binding neurite-outgrowth promoting factor | |
| AU3222993A (en) | Neurotrophic factor | |
| WO1994012634A1 (en) | Neurotrophic factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |